tbResList Print — Tras Trastuzumab

Filters: qv=260, qv2=%, rfv=%

Product

Tras Trastuzumab
Description: <b>Trastuzumab</b> is a targeted therapy used in the treatment of certain types of cancer, most notably HER2-positive breast cancer. <br>
<br>
It specifically targets the human epidermal growth factor receptor 2 (HER2), a protein that is overexpressed in some types of breast cancer and other cancers.<br>
-Is a Her2 inhibitor used in breast cancer. <br>
<br>
Trastuzumab has revolutionized the treatment of HER2-positive breast cancer, significantly improving both response rates and overall survival.<br>

Pathway results for Effect on Cancer / Diseased Cells

NA, unassigned(tgid=0) ⓘ

CR↑, 1,   EFS↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp8↑, 1,   p‑p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 1,   HER2/EBBR2↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

p62↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   mTOR↓, 1,   PI3K↓, 2,   p‑STAT3↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

PD-L1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 2,   eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

HER2/EBBR2↓, 2,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 1,   toxicity↝, 1,  
Total Targets: 24

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
2025ASCORBYL PALMITATE ENHANCES ANTI-PROLIFERATIVE EFFECT OF TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER CELLSR. Serttas—https://exp-oncology.com.ua/index.php/Exp/article/view/4960
2017Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cellsCarolina D’AlesioPMC5670707https://pmc.ncbi.nlm.nih.gov/articles/PMC5670707/0
2025Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cellsSevda Jafari—https://www.nature.com/articles/s41598-025-25098-x0
2017Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trialsZhi-qiao XuPMC5353336https://pmc.ncbi.nlm.nih.gov/articles/PMC5353336/0